Policy

Switching to Biosimilar Etanercept Shows No Impact on Efficacy, Safety Across 18 Trials

March 16th 2026

By Skylar Jeremias

Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, easing concerns and highlighting nocebo challenges.

Gaps in Knowledge Persist Around Biosimilar Insulin Switching, Review Finds

March 12th 2026

By Skylar Jeremias

Scoping review shows clinicians and patients still worry about biosimilar insulin switching, devices and safety—evidence gaps shape insulin product swaps.

Global Biosimilar Market Sees Structural Shifts, Regulatory Hurdles, and Pipeline Gains

March 10th 2026

By Skylar Jeremias

Global biosimilar market shifts: Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.

FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies

March 9th 2026

By Skylar Jeremias

Biologics eat 51% of drug spending despite being 5% of prescriptions, but the FDA's new draft guidance hopes more competition can close that gap.

Clinician Confidence in Ophthalmology Biosimilars Remains Low Across Europe

March 6th 2026

By Skylar Jeremias

A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.

Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 3rd 2026

By Skylar Jeremias

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27th 2026

By Skylar Jeremias

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to cost-effective therapies.

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26th 2026

By Alex Keeton

Biosimilar Competition Linked to Lower Out-of-Pocket Costs for Medicare Patients

January 21st 2026

By Skylar Jeremias

Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic therapies and improving access.

What Australia’s Experience Reveals About Biosimilar Adoption and Pricing

January 15th 2026

By Skylar Jeremias

Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization amid tighter health care budgets.